Accelerated And Non-Accelerated dTMS Protocols Both Effective In Treatment Of MDD

left dlPFC stimulation at 20 Hz for 1200 pulses. PHQ-9 & GAD-7 were completed weekly while CHRT, QIDS, & Zung were given pre/post treatment course. Results: 57.36% of patients achieved remission ( 70% improvement on PHQ-9) and significant moderate effect was found after rTMS in overall performance on the CRT (d 1⁄4 -.38, p < .001), TMT (d 1⁄4 -.39, p < .001), & PDQ-5-D (d 1⁄4 -.82, p < .001). Significant smaller effect was found in the NBack correct responses (d 1⁄4 -.24, p 1⁄4 .0005), NBack longer streak (d 1⁄4 -.27, p 1⁄4 .0000), DSST best reaction time (d 1⁄4 .15, p 1⁄4 .05), DSST nodes completed (d1⁄4 -.21, p1⁄4 .0004), DSST longest streak (d1⁄4 -.16, p1⁄4 .04), TMT errors (d 1⁄4 .23, p 1⁄4 .004), and TMT longest streak (d 1⁄4 -.20, p 1⁄4 .01). Conclusions: Detrimental cognitive effects were not observed or reported. Cognitive performance after TMS suggests patients’ executive function, working memory, processing speed, and attention may have improved. Funding: Patients who were already seeking TMS treatment were financially responsible for their acute courses of TMS treatment. Therapy may have been covered by insurance and/or privately paid for by the patient. Tablets used to conduct the assessments and for TMS therapy documentation are privately owned by our company, a private clinical practice. THINC-it Cognitive Screener is a free application used as part of our standard of care for all patients.